5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

Richard J. Gralla, David Osoba, Mark G. Kris et al. · Journal of Clinical Oncology · 1999 · 670 citations

Preclinical Therapeutics, Perioperative Medicine, Evidence-based Medicine +27

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

Richard J. Gralla, M. Lichinitser, S. van der Vegt et al. · Annals of Oncology · 2003 · 471 citations

Emetogenic Chemotherapy, Oncology, Chemotherapy-induced Nausea +5

Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

Steven M. Grunberg, Robert Deuson, Panagiotis Mavros et al. · Cancer · 2004 · 465 citations · Full text

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 464 citations

Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist

Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer · 2003 · 404 citations · Full text